5-fluorouracil + OK-432 + carmofur + mitomycin C

This is a combination regimen consisting of four agents: - **5-fluorouracil (5-FU):** An antimetabolite and pyrimidine analog that inhibits thymidylate synthase, blocking DNA synthesis and leading to cell death. It is widely used in the treatment of various cancers, including colorectal, anal, gastric, pancreatic, breast, and cervical cancers[6][9]. - **OK-432:** A lyophilized preparation of a low-virulence strain of *Streptococcus pyogenes* treated with penicillin G. It acts as an immunomodulator by stimulating immune responses (notably cytokine production) and has been used mainly in cancer immunotherapy and for lymphangioma. - **Carmofur:** An oral fluoropyrimidine derivative related to 5-FU; it acts as an antimetabolite by inhibiting thymidylate synthase after conversion to 5-FU in vivo. Used primarily for colorectal cancer. - **Mitomycin C:** An antitumor antibiotic that functions as a bifunctional alkylating agent after activation in vivo. It cross-links DNA strands, inhibiting DNA synthesis and function; it is cell cycle phase-nonspecific[7][10]. The combination aims to leverage cytotoxic effects on tumor cells via multiple mechanisms—direct inhibition of DNA synthesis (by 5-FU/carmofur/mitomycin C) plus immune system stimulation (by OK-432). This multi-agent approach may be considered for advanced or refractory malignancies where both cytotoxic chemotherapy and immunomodulation are desired.

Other names

5-FU + OK-432 + carmofur + mitomycin C